Psoriasis is a chronic disease that can affect many areas of the body. The use of topical corticosteroids (TCS) is a common treatment, although long-term safety of TCS remains a concern.
A recent article in Dermatology Times cites a Journal of Drugs in Dermatology study which examines how Topical Halobetsol Propionate 0.01% lotion appears to “safely and quickly improve lower-extremity psoriatic lesions,” over typical TCS treatments.
“A post hoc analysis of data from phase 3 studies investigating the e fficacy of halobetasol propionate 0.01% lotion for treating moderate-to-severe plaque psoriasis showed that the topical corticosteroid was associated with rapid improvement, and findings should help dermatologists with treatment decisions for patients with disease involving leg lesions, said Neal Bhatia, M.D., director of clinical dermatology at Therapeutics Clinical Research, San Diego, and the lead author of the paper.”
At the conclusion of the eight-week treatment, the rate of success was significantly higher for patients randomized to once-daily treatment with halobetasol 0.01% lotion compared with vehicle-treated controls (P<.001 for both comparisons).
View Article Now
You May Also Like
JDD in the News: Topical Nonsteroidals for Chronic Hand Eczema
JDD in the News: Topical Nonsteroidals for Chronic Hand Eczema
Physician’s Weekly interviewed dermatologist Geeta Yadav, MD, for her perspective on the March Journal of Drugs in Dermatology study, “Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.”…
Dermatology Roundup: NPF Clarifies Definition of Psoriasis Disease Severity
Dermatology Roundup: NPF Clarifies Definition of Psoriasis Disease Severity
Survey reveals higher likelihood of reported delays in accessing melanoma care among patients with skin of color The National Psoriasis Foundation (NPF) has a new position statement that clarifies the…
JDD in the News: Skin and Hair Reactions from GLP-1 Agonists
JDD in the News: Skin and Hair Reactions from GLP-1 Agonists
Medscape highlighted a January Journal of Drugs in Dermatology study on the incidence of skin and hair effects from GLP-1 agonists. The study, “Cutaneous Adverse Events Associated With GLP-1 Receptor…
